ArticleJournal for immunotherapy of cancer2025
Biomineralized engineered
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tetrandrine-based in situ vaccination via multifunctional Mn²⁺-hyaluronic acid hydrogel loading gelatinase-responsive nanoparticles.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombining chemotherapy with immunotherapy is a promising strategy to enhance in situ immunity by increasing antigen exposure and inflammation in the tumor microenvironment (TME). However, the inconvenience of separate administration and the randomness of delivery can diminish the synergistic effect of these treatments. An efficient co-delivery system to optimize chemo-immunotherapy is urgently needed.
methodsWe have previously developed an engineered
resultsOn intratumoral administration, D&V@FOLactis exhibited pH-responsive drug release, primarily inducing immunogenic cell death and enhancing antigen exposure. Subsequently, FOLactis acted as immunopotentiators to recruit immune cells and maintain long-lasting effect. D&V@FOLactis was instrumental in thoroughly improving TME, activating T-cell responses, suppressing both "cold" and "hot" tumors with abscopal effect, and prolonging survival. In the clinical trial involving three patients, the combination of D&V@FOLactis with radiotherapy suggested potential improvements in systemic immunity and a possible reduction in multiple types of tumors.
conclusionsWe achieved the sequential activation of synergistic chemo-immunotherapy using an all-in-one biomineralized strategy. This study marked the first instance of biomineralizing probiotics with Mg-MOFs, creating a biosafe and versatile platform for combined in situ vaccination treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.